Table 2.
Switching from Interferon Beta
| Avonex® | Betaferon® | Extavia® | Plegridy® | Rebif® | |
|---|---|---|---|---|---|
| Discontinuation | 257/618 (41.6%) | 175/348 (50.2%) | 38/69 (55.0%) | 102/259 (39.3%) | 543/1220 (44.4%) |
| No further DMT record | 45/618 (7.3%) | 45/348 (12.9%) | 7/69 (10.1%) | 23/259 (8.8%) | 180/1220 (14.7%) |
| Switch to other DMT | 212/618 (34.3%) | 130/348 (37.3%) | 31/69 (44.9%) | 79/259 (30.5%) | 363/1220 (29.7%) |
| After, months | 23.2 ± 12.7 | 22.5 ± 12.6 | 19.3 ± 13.2 | 11.7 ± 8.1 | 23.3 ± 12.6 |
| HR | 1.12 | 1.59 | 1.89 | 2.13 | reference |
| 95%CI | 0.93, 1.34 | 1.30, 1.96 | 1.29, 2.77 | 1.59, 2.85 | |
| p-value | 0.20 | < 0.01 | < 0.01 | < 0.01 | |
| To: | (out of 212) | (out of 130) | (out of 31) | (out of 79) | (out of 363) |
| Aubagio® | 32 (15.1%) | 26 (20.0%) | 6 (19.3%) | 6 (7.6%) | 35 (9.6%) |
| Avonex® | – | 4 (3.1%) | – | 19 (24.0%) | 9 (2.5%) |
| Betaferon® | 2 (0.9%) | – | 6 (19.3%) | 3 (3.8%) | 4 (1.1%) |
| Copaxone® | 10 (4.7%) | 7 (5.4%) | – | 12 (15.2%) | 12 (3.3%) |
| Extavia® | – | 2 (1.5%) | – | – | – |
| Gilenya® | 40 (18.9%) | 26 (20.0%) | 5 (16.1%) | 10 (12.7%) | 98 (27.0%) |
| Lemtrada® | – | – | – | – | 1 (0.3%) |
| Plegridy® | 72 (34.0%) | 11 (8.5%) | 3 (9.7%) | – | 45 (12.4%) |
| Rebif® | 7 (3.3%) | 2 (1.5%) | 3 (9.7%) | 4 (5.1%) | – |
| Tecfidera® | 44 (20.7%) | 45 (34.6%) | 7 (22.6%) | 22 (27.8%) | 131 (36.1%) |
| Tysabri® | 5 (2.4%) | 7 (5.4%) | 1 (3.3%) | 3 (3.8%) | 27 (7.4%) |
Table shows number and percentage of individual treatment periods with Interferon Beta discontinuation. Number and percentage of individual treatment periods is also reported for those without further DMT record, and for those switching to another DMT (with time to switch and DMTs individuals were switched to). HR, 95%CI, and p-values are reported from Cox regression models evaluating the rate of switch for different Interferon Beta formulations; covariates were age, sex, and treatment duration (Rebif® was used as reference in the statistical models)